112 related articles for article (PubMed ID: 3449068)
1. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
[TBL] [Abstract][Full Text] [Related]
2. Independent of etozolin elimination of kidney function. Single dose experiments in patients with renal insufficiency.
Knauf H; Hasenfuss G; Wais U; Schollmeyer P; Mutschler E
Arzneimittelforschung; 1980; 30(10):1791-3. PubMed ID: 7192116
[TBL] [Abstract][Full Text] [Related]
3. Assay of etozolin and its main metabolite, ozolinone, in plasma by high performance liquid chromatography.
Hengy H; Vollmer KO; Gladigau V; Kölle EU
Arzneimittelforschung; 1980; 30(10):1788-90. PubMed ID: 7192115
[TBL] [Abstract][Full Text] [Related]
4. [Comparative studies on the diuretic activities of Etozolin and a reference compound in normal volunteers (author's transl)].
Biamino G
Arzneimittelforschung; 1977; 27(9a):1814-7. PubMed ID: 578772
[TBL] [Abstract][Full Text] [Related]
5. Placental transfer of etozolin and ozolinone during the first half of gestation in man.
Nau H; Steldinger R; Ivan E
Eur J Clin Pharmacol; 1982; 23(3):253-60. PubMed ID: 7173295
[TBL] [Abstract][Full Text] [Related]
6. Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis.
Zhang W; Yue B; Wang GQ; Lu SL
Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):577-80. PubMed ID: 14607690
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study.
Funasaki T; Tsutsumi M; Takase S; Tsuchishima M; Ueshima Y; Urashima S; Shimanaka K; Itoh T; Kawahara H
Am J Gastroenterol; 1999 Sep; 94(9):2475-81. PubMed ID: 10484011
[TBL] [Abstract][Full Text] [Related]
8. Components of the renin-angiotensin-aldosterone system in plasma and ascites in hepatic cirrhosis.
Kuiper JJ; Boomsma F; van Buren H; de Man R; Danser AH; van den Meiracker AH
Eur J Clin Invest; 2008 Dec; 38(12):939-44. PubMed ID: 19021719
[TBL] [Abstract][Full Text] [Related]
9. The influence of ascites on the pharmacokinetics of amikacin.
Lanao JM; Dominguez-Gil A; Macias JG; Diez JL; Nieto MJ
Int J Clin Pharmacol Ther Toxicol; 1980; 18(2):57-61. PubMed ID: 7372376
[TBL] [Abstract][Full Text] [Related]
10. [Metabolism and kinetics of ampicillin elimination in cirrhosis. Therapeutical consequences (author's transl)].
Chalas J; Labayle D; Macarrio J; Barraud D; Lindenbaum A; Buffet C; Chaput JC
Sem Hop; 1980 Mar 8-15; 56(9-10):464-9. PubMed ID: 6244668
[TBL] [Abstract][Full Text] [Related]
11. Elevation of cytokines in peritoneal fluid and blood in patients with liver cirrhosis.
Eriksson AS; Gretzer C; Wallerstedt S
Hepatogastroenterology; 2004; 51(56):505-9. PubMed ID: 15086192
[TBL] [Abstract][Full Text] [Related]
12. Bradykinin in the ascitic fluid of patients with liver cirrhosis.
Cugno M; Salerno F; Nussberger J; Bottasso B; Lorenzano E; Agostoni A
Clin Sci (Lond); 2001 Dec; 101(6):651-7. PubMed ID: 11724653
[TBL] [Abstract][Full Text] [Related]
13. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
14. [Effect of the diuretic Etozolin (Gö 687) on renal elimination of water and solutes in subjects with normal renal function (author's transl)].
Scheitza E
Arzneimittelforschung; 1977; 27(9a):1804-6. PubMed ID: 578770
[TBL] [Abstract][Full Text] [Related]
15. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
Cho HS; Park GT; Kim YH; Shim SG; Kim JB; Lee OY; Choi HS; Hahm JS; Lee MH
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):324-31. PubMed ID: 14695699
[TBL] [Abstract][Full Text] [Related]
16. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
[TBL] [Abstract][Full Text] [Related]
17. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
18. [Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications].
Gentilini P; Laffi G; La Villa G; Casini-Raggi V; Romanelli RG; Buzzelli G; Mazzanti R; Marra F; Pinzani M; Zignego AL
Ann Ital Med Int; 1996 Oct; 11 Suppl 2():23S-29S. PubMed ID: 9004817
[TBL] [Abstract][Full Text] [Related]
19. [Dynamics of ascitic fluid in decompensated cirrhosis].
Milani A; Mazzone M; Rossi L
Recenti Prog Med; 1999 Feb; 90(2):94-9. PubMed ID: 10208100
[TBL] [Abstract][Full Text] [Related]
20. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
Alam I; Bass NM; Bacchetti P; Gee L; Rockey DC
Am J Gastroenterol; 2000 Jan; 95(1):199-203. PubMed ID: 10638583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
